Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Trial of Prednisone in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000178
Recruitment Status : Completed
First Posted : November 1, 1999
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:
National Institute on Aging (NIA)

Brief Summary:
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Prednisone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Multicenter Trial of Prednisone in Alzheimer's Disease






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with Alzheimer's disease who are in stable medical condition

Exclusion Criteria:

  • Patients with diabetes or severe osteoporosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000178


Locations
Show Show 19 study locations
Sponsors and Collaborators
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Leon Thal, MD. University of California, San Diego
Publications of Results:
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00000178    
Other Study ID Numbers: IA0002
3U01AG010483-08S2 ( U.S. NIH Grant/Contract )
First Posted: November 1, 1999    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: February 2005
Keywords provided by National Institute on Aging (NIA):
Alzheimer's disease
Prednisone
Anti-inflammatory agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents